切换至 "中华医学电子期刊资源库"
高级检索
中华神经创伤外科电子杂志

中华神经创伤外科电子杂志 ›› 2015, Vol. 01 ›› Issue (05) : 4 -8. doi: 10.3877/cma.j.issn.2095-9141.2015.05.002

所属专题： 文献；

临床研究

血压水平与高血压脑卒中发病风险的关系研究
纵振坤1, 庞慧2,†(), 韩冰2, 付强2   
  1. 1. 221002　徐州，徐州医学院附属医院神经外科
    2. 徐州市中心医院心内科
  • 收稿日期:2015-07-27 出版日期:2015-10-15
  • 通信作者: 庞慧

Levels of blood pressure are associated with the prevalence of stroke in hypertension patients

Zhenkun Zong1, Hui Pang2,†(), Bing Han2, Qiang Fu2   

  1. 1. Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical College, Xuzhou Medical College Xuzhou 221002, China
    2. Department of Cardiovascular Medicine, Central Hospital of Xuzhou, Xuzhou Clinical School of Xuzhou Medical College, Xuzhou 221002, China
  • Received:2015-07-27 Published:2015-10-15
  • Corresponding author: Hui Pang
  • About author:
    Corresponding author: Pang Hui, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

纵振坤, 庞慧, 韩冰, 付强. 血压水平与高血压脑卒中发病风险的关系研究[J]. 中华神经创伤外科电子杂志, 2015, 01(05): 4-8.

Zhenkun Zong, Hui Pang, Bing Han, Qiang Fu. Levels of blood pressure are associated with the prevalence of stroke in hypertension patients[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2015, 01(05): 4-8.

目的

探讨血压与其他危险因素并存时对于高血压脑卒中患病率的影响，从而有效预防处于危险状态人群卒中的初发以及卒中幸存者的卒中再发。

方法

选择自2014年5月至2015年5月在徐州市中心医院心内科住院治疗2 396例原发性高血压患者的病例资料，包括年龄、性别、体质指数(BMI)、血压、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、空腹血糖(GLU)、同型半胱氨酸(Hcy)以及疾病既往史等，采用Logistic回归模型，引入交叉乘积项分析血压与其他危险因素对于原发性高血压脑卒中患病率的影响。

结果

2 396例原发性高血压患者中，与血压达标者相比，未达标者空腹GLU的水平显著升高[(6.13±1.91) mmol/L对比(6.45±2.24) mmol/L，t=2.652，P=0.003]，而HDL-C的含量显著降低[(39.27±11.97) mmol/L对比(36.28±11.45) mmol/L，t=4.702，P=0.000]，合并糖尿病、脑卒中及高同型半胱氨酸血症的比例明显增加(χ2分别为4.910，140.630，44.284，P<0.05)。在年龄45~74岁以及BMI、空腹GLU、非HDL-C、TG、Log Hcy的不同分层中，高血压患者随着血压水平的升高，脑卒中的患病率逐渐增加(P<0.05)。

结论

血压与Hcy的交互作用能够增加高血压患者脑卒中的患病率。对于高血压合并脑卒中患者，年龄与性别对非HDL-C、TG水平的影响存在交互。

关键词: 血压, 脑卒中, 同型半胱氨酸, 血脂障碍
Objective

To analyze both blood pressure and other risk factors associated with the prevalence of stroke in hypertension patients for the prevention of an initial stroke and future stroke among survivors of stroke.

Methods

Detailed information of 2 396 patients with essential hypertension were collected including age, gender, body mass index (BMI), blood pressure (BP), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting glucose (GLU), homocysteine (Hcy), and past history of diabetes mellitus, hyperlipemia, stroke and hyperhomocysteinemia. The detectable interaction between BP and stratified factors is examined by adding the BP × stratified factors cross-product to a logistic regression analysis of the hypertension participants.

Results

A total of 2 396 patients with primary hypertension were enrolled in this study. Hypertension patients with BP≥140/90 mmHg had a significantly higher fasting GLU(6.13±1.91 vs. 6.45±2.24, t=2.652, P=0.003), lower HDL-C level (39.27±11.97 vs. 36.28±11.45, t=4.702, P=0.000) than that of patients with BP<140/90 mmHg, as was also their exposure to diabetes mellitus, stroke and hyperhomocysteinemia (χ2=4.910, 140.630, 44.284, respectively, P<0.05). An increasing level of blood pressure was associated with higher stroke risk the condition of age range 45-74, and full scope of BMI, fasting GLU, non-HDL-C, TG and Log Hcy(P<0.05).

Conclusions

Among the hypertension participants, significant interaction on stroke risk was observed between blood pressure and Log Hcy. Age and gender interacted with non-HDL-C and TG in hypertension patients with stroke.

Key words: Blood pressure, Stroke, Homocysteine, Dyslipidemia
表1 原发性高血压患者降压治疗达标者与未达标者的基本情况比较
变量 降压达标(n=394) 降压未达标(n=2002) t/χ2值 P值
年龄(岁) 60.9±8.0 60.7±8.9 0.456 0.624
男[n(%)] 250(63.45) 1224(61.14) 0.649 0.388
BMI (kg/m2) 24.73±3.45 24.65±3.48 0.418 0.667
吸烟[n(%)] 185(46.95) 889(44.41) 0.765 0.352
饮酒[n(%)] 146(37.06) 738(36.86) 0.000 0.942
SBP (mmHg) 124.94±9.84 161.31±21.75 32.539 0.000
DBP (mmHg) 77.45±7.06 94.93±13.05 26.037 0.000
空腹GLU (mmol/L) 6.13±1.91 6.45±2.24 2.652 0.003
TC (mmol/L) 4.95±0.95 4.87±1.03 1.498 0.134
HDL?C (mmol/L) 1.01±0.31 0.94±0.30 4.702 0.000
非HDL?C (mmol/L) 3.94±0.91 3.93±0.98 0.125 0.894
TG (mmol/L) 1.80±0.93 1.85±0.98 0.874 0.383
Hcy (μmol/L) 17.33±14.85 18.02±13.38 0.918 0.356
基础疾病[n(%)] ? ? ? ?
? 糖尿病 84(21.32) 537(26.82) 4.910 0.023
? 高脂血症 199(50.51) 954(47.65) 0.964 0.300
? 脑卒中 166(42.13) 1 458(72.83) 140.630 0.000
? 高Hcy血症 169(42.89) 1 224(61.14) 44.284 0.000
表2 血压对于原发性高血压脑卒中患病率的影响[OR(95% CI)]
变量 血压(mmHg) P值(趋势分析) P值(交互作用)
<140/90(n=394) 140～159/90～99(n=827) 160～179/100～109(n=597) ≥180/110(n=578)
年龄(岁) ? ? ? ? ? 0.341
? ≤44(n=101) 1 / / / 0.206 ?
? 45～59(n=860) 1 1.584(1.010～2.485) 6.501(3.834～11.024) 34.103(16.798～69.233) 0.000 ?
? 60～74(n=1352) 1 1.597(1.122～2.272) 5.344(3.584～7.968) 25.839(14.448～46.213) 0.000 ?
? ≥75(n=83) 1 / / / 0.076 ?
BMI(kg/m2) ? ? ? ? ? 0.318
? <24(n=1034) 1 1.608(1.064～2.430) 7.965(4.853～13.075) 33.870(16.160～70.987) 0.000 ?
? 24～27.9(n=992) 1 1.518(1.026～2.247) 4.911(3.110～7.756) 25.970(13.014～51.825) 0.000 ?
? ≥28(n=370) 1 0.866(0.447～1.678) 2.824(1.380～5.778) 15.564(6.484～37.358) 0.000 ?
空腹GLU(mmol/L) ? ? ? ? ? 0.109
? <6.1(n=1475) 1 1.188(0.863～1.635) 4.178(2.906～6.007) 30.490(16.535～56.225) 0.000 ?
? 6.1～6.9(n=409) 1 2.625(1.335～5.164) 9.919(4.599～21.394) 32.884(12.908～83.775) 0.000 ?
? ≥7.0(n=512) 1 1.502(0.829～2.721) 10.209(4.271～24.402) 13.540(5.862～31.276) 0.000 ?
非HDL～C(mmol/L) ? ? ? ? ? 0.646
? <160(n=1437) 1 1.288(0.922～1.799) 4.915(3.287～7.350) 28.213(15.045～52.903) 0.000 ?
? 160～189(n=611) 1 2.374(1.390～4.054) 7.739(4.275～14.008) 42.952(18.326～100.671) 0.000 ?
? ≥190(n=348) 1 0.826(0.376～1.815) 3.816(1.609～9.048) 12.649(4.627～34.581) 0.000 ?
TG(mmol/L) ? ? ? ? ? 0.543
? <150(n=1288) 1 1.423(0.991～2.045) 5.479(3.596～8.348) 27.952(15.500～50.410) 0.000 ?
? 150～199(n=485) 1 1.748(0.958～3.187) 10.471(5.115～21.437) 19.606(8.272～46.470) 0.000 ?
? ≥200(n=623) 1 1.315(0.793～2.180) 3.597(2.015～6.423) 59.113(17.201～203.144) 0.000 ?
Log Hcy ? ? ? ? ? 0.000
? <1.09(n=783) 1 1.305(0.814～2.092) 3.935(2.323～6.668) 18.520(9.412～36.441) 0.000 ?
? 1.09～1.23(n=862) 1 1.438(0.936～2.210) 6.031(3.661～9.935) 28.930(14.040～59.609) 0.000 ?
? >1.23(n=751) 1 1.397(0.877～2.225) 6.551(3.644～11.780) 44.399(15.285～128.964) 0.000 ?
图1 Log Hcy和血压对于高血压脑卒中患病率的交互作用
图2 年龄和性别对于高血压脑卒中患者非HDL-C水平的影响
图3 年龄和性别对于高血压脑卒中患者TG水平的影响
[1]
Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2014, 45(7): 2160-2236.
[2]
Okin PM, Hille DA, Kjeldsen SE, et al. Impact of lower achieved blood pressure on outcomes in hypertensive patients[J]. J Hypertens, 2012, 30(4): 802-810.
[3]
Sipahi I, Swaminathan A, Natesan V, et al. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials[J]. Stroke, 2012, 43(2): 432-440.
[4]
Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension[J]. Cochrane Database Syst Rev, 2012, 8(4): CD002003.
[5]
Ogihara T, Matsuzaki M, Umemoto S, et al. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial[J]. Hypertens Res, 2012, 35(4): 441-448.
[6]
Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial[J]. J Hypertens. 2011, 29(8): 1649-1659.
[7]
Antoniades C, Antonopoulos AS, Tousoulis D, et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials[J]. Eur Heart J, 2009, 30(1): 6-15.
[8]
Spence JD, Bang H, Chambless LE, et al. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis[J]. Stroke, 2005, 36(11): 2404-2409.
[9]
Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial[J]. JAMA, 2004,291(5): 565-575.
[10]
Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis[J]. Lancet, 2007, 369(9576): 1876-1882.
[11]
Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary[J]. J Clin Lipidol, 2014, 8(5): 473-488.
[12]
Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes[J]. Stroke, 2009, 40(4): 1405-1409.
[13]
Castilla-Guerra L, Fernandez-Moreno Mdel C, Chaturvedi S, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack[J]. Neurology, 2009, 73(3): 248.
[14]
Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study[J]. Neurology, 2008, 70(24 Pt 2): 2364-2370.
[15]
Mora S, Glynn RJ, Boekholdt SM, et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)[J]. J Am Coll Cardiol, 2012, 59(17): 1521-1528.
[16]
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the general population[J]. JAMA, 2008, 300(18): 2142-2152.
[17]
Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies[J]. Atherosclerosis, 2009, 203(2): 331-345.
[18]
Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease[J]. JAMA, 2009, 302(18): 1993-2000.
[19]
Amarenco P, Goldstein LB, Callahan A 3rd, et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL) trial[J]. Atherosclerosis, 2009, 204(2): 515-520.
[20]
Uhlig K, Patel K, Ip S, et al. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis[J]. Ann Intern Med, 2013, 159(3): 185-194.
[1] 邓华梅, 袁札根, 曾德荣, 潘珊珊, 张葆青, 欧爱华, 曹学伟. 全膝关节置换术中气压止血带应用效果与影响因素分析[J]. 中华关节外科杂志(电子版), 2023, 17(06): 788-794.
[2] 靳茜雅, 黄晓松, 谭诚, 蒋琴, 侯昉, 李瑶悦, 徐冰, 贾红慧, 刘文英. 产前他克莫司治疗对先天性膈疝大鼠病理模型肺血管重构的影响[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 428-436.
[3] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[4] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[5] 赫嵘, 贾哲, 张珂, 李代京, 张萌, 蒋力. 基于PSM分析腹腔镜肝切除联合Hassab术治疗合并门静脉高压症肝癌疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 376-383.
[6] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[7] 尚慧娟, 袁晓冬. 机械取栓术后应用依达拉奉右崁醇对急性缺血性脑卒中预后的改善[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 295-301.
[8] 运陌, 李茂芳, 王浩, 刘东远. 微创穿刺引流联合吡拉西坦、乌拉地尔治疗基底节区高血压性脑出血的临床研究[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 278-285.
[9] 廖家权, 吴波, 唐昌敏. 体外冲击波联合肌电生物反馈对脑卒中后足下垂的影响[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 286-292.
[10] 刘政委, 仪立志, 尹夕龙, 孔文龙, 纠智松, 张文源. 锥颅血肿外引流与神经内镜手术治疗老年基底节区高血压性脑出血的疗效分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 299-303.
[11] 孙畅, 赵世刚, 白文婷. 脑卒中后认知障碍与内分泌激素变化的关系[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 471-476.
[12] 张许平, 刘佳成, 张舸, 杜艳姣, 李韶, 商丹丹, 王浩, 李艳, 段智慧. CYP2C19基因多态性联合血栓弹力图指导大动脉粥样硬化型非致残性缺血性脑血管事件患者抗血小板治疗的效果[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 477-481.
[13] 杨海华, 袁景林, 周晓梅, 牛军伟. RNF213基因突变所致烟雾病一家系病例临床分析并文献复习[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 495-498.
[14] 李昕, 李永凯, 江树青, 夏来百提姑·赛买提, 杨建中. 急性缺血性脑卒中静脉溶栓后出血转化相关危险因素分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 331-336.
[15] 邓颖, 黄山, 胡慧秀, 孙超. 老年缺血性脑卒中患者危险因素聚集情况分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 344-349.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号